MediTech Chronicles

Lilly sells R&D campus to Covance in the pioneering deal.. Yesterday, Eli Lilly made a significant step toward outsourcing with the sale of a significant R&D site to contract research group Covance and the formation of new contracts with Quintiles and i3.  Lilly is adopting a road that is less usual in R&D but is already well-trodden in the pharmaceutical manufacturing industry. When faced with excess capacity, several pharmaceutical companies chose to sell off operations, frequently including legacy contracts, to management buyout teams or reputable contract manufacturers. The Lilly/Covance deal is one of the first large-scale examples of this type of facility sale in early-stage drug development – a function that until recently was jealously guarded within the walls of big pharma companies.  According to the terms of the agreement, Covance will offer jobs to 260 Lilly employees who work in non-Good Laboratory Practice (GLP) toxicology, in vivo pharmacology, quali...

Dr Reddy's in collaboration with SkyePharma on delivery system Using two of SkyePharma's unique drug delivery systems, the UK company SkyePharma has agreed to conduct a feasibility study on an unnamed product with Dr Reddy's Laboratories of India. The study's expenses will be covered by Dr. Reddy's, and SkyePharma will also get a "small" up-front payment, according to the two businesses. Full development activities would start later this year, they stated, if the feasibility study is successful.  With organizations like GlaxoSmithKline, Roche, Schiele, Novartis, AstraZeneca, Nitec, and Abbott in the past, SkyePharma has collaborated on the development of both licensed pharmaceuticals as well as drugs in development that use the oral, inhalation, and topical drug delivery technologies of the UK company.  The FDA recently requested a second clinical study to gather additional efficacy data on the bronchodilator/steroid combination found in SkyePharma's p...

Researchers target ocular drug delivery market Researchers have developed a drug delivery device which attaches to the eye and could negate the need for repeat injections. The team from the University of Southern California has created a simple polymer device which is inserted under the conjunctiva and delivers a therapeutic to the affected area. In time the device could come to replace the intravitreal injections which patients suffering from glaucoma and related eye diseases currently have to be administered with.  Ellis Meng, researcher on the project, was keen to emphasise further refinements are in the pipeline. She said: " This prototype isn't optimally sized; it's our first go at proving the concept. We're now building a next-generation device ."  The one centimetre long prototype consists of a refillable reservoir sutured to the sclera which contains the therapeutic. Leading off this is a flexible tube which is inserted into the side of the eye and throug...

Competition intensifying for diabetes subjects; Acurian Acurian, a company that specializes in patient recruiting, has reached a significant business milestone with the addition of more than 50 percent of the country's type 2 diabetes population to its database.  Approximately 8 million of the estimated 16 million diagnosed type 2 or adult-onset diabetes are already on the company's books. The business maintains a database of almost 40 million patients in total. According to Rick Malcolm, PhD, CEO of Acurian, "It should come as no surprise that diabetes is one of the most strong indications in our database. However, given the fierce rivalry for research participants in this therapeutic field, the fact that more than half of the nation's type 2 diabetics are present and open to learning about clinical trials is definitely important to note.  According to him, Acurian can assist trial sponsors in gaining access to huge numbers of diabetic patients so they can successfull...

Sun Pharma eyes tie-ups in Europe DRUG major Sun Pharmaceuticals Industries Ltd is looking for partnerships in the European market to fuel its next level of growth in the international arena.  The company, however, has dropped its plans to raise funds of about $350 million through a foreign currency convertible bond issue. To support the company's domestic and export plans, an investment of about Rs 100 crore has been earmarked towards beefing up capacity.  A bulk of the amount would go into capacity expansion at Sun Pharma's facilities in Panoli and Ahmednagar, part of it would also go towards Sun's Halol plant, that had received US regulatory approval in the quarter under review.  An estimated Rs 15 crore would be infused into the cephalosporin bulk active plant that comes into the Sun fold, through its merger with Phlox Pharma. Part of the funds would also go towards upgrading machinery in other facilities belonging to Sun Pharma, officials said.

FDA lists drugs with potential safety issues A list of drugs currently being evaluated for potential safety issues by the US Food and Drug Administration (FDA) has been posted on its website. The list has been published under laws brought in last September that require the FDA to inform the public of new safety information or potential signals of serious risk. Information is to be published each quarter detailing drugs that have been identified as having potential safety issues based on reports in the FDA’s Adverse Event Reporting System (AERS). The list is intended to inform patients of potential safety issues and the agency has been keen to stress that there is no definite or casual relationship between the listed drugs and their risks.  The list is part of the FDA’s goal of improving communication with patients but could cause more harm than good if incorrectly interpreted .

Sandoz boosts Canadian production capacity Sandoz Canada, a unit of Novartis’ generics arm, has opened a second manufacturing plant at its site in Boucherville, Quebec, boosting local production capacity 66 per cent. The plant, which is due to be fully operational by mid September, comprises manufacturing, laboratory and warehousing space that the firm believes will give it the flexibility it needs to keep pace with increasing market demands.  Richard Saynor, Head of Commercial Operations for Asia-Pacific, Latin America, Canada and Turkey says that: “The new plant in Boucherville is highly significant for our Canadian operations, and for Sandoz worldwide. It will enable us to triple our production capacity in both vials and ampoules.  The new plant will manufacture a range of medicines, including opiate analgesics. We currently make 85 different molecules in Boucherville and the plant supplies products globally, although the bulk of sales are in Canada and the US.

Cholesterol- lowering drug given cancer all-clear Cancer fears about a cholesterol- lowering drug have turned out to be a 'statistical blip'. A class of cholesterol- lowering drug that had been implicated in a cancer scare has been cleared by epidemiologists using the results from two large ongoing clinical trials.   Preliminary results from the relatively small SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study had triggered the cancer scare in July. The trial was designed to investigate whether a combination of these two cholesterol- lowering drugs would help in cases of aortic stenosis, where a key heart valve is partially blocked. Simvastatin, a statin that has already been used in other drugs, works by blocking cholesterol synthesis in the body. The newer ezetimibe works by blocking the absorption of cholesterol from the gut.  A unusual pre-publication announcement from the SEAS study reported that, while the therapy did not help very much in aortic stenosis, canc...